047053. 5. Fox CS: Cardiovascular disease danger variables, variety two diabetes mellitus, plus the

047053. five. Fox CS: Cardiovascular disease risk elements, variety two diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med 2010, 20(three):905. 6. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Emerging danger things collaboration. Diabetes mellitus, fasting blood glucose concentration, and threat of vascular disease: a collaborative meta-analysis of 102 potential studies. Lancet 2010, 375:2215222. 7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular illness mortality in middle-aged guys. JAMA 2002, 288(21):2709716. eight. Leuzzi C, Marzullo R, Modena MG: Is menopause a risk issue for ischemic heart disease in females G Ital Cardiol 2012, 13:40106. 9. Saltiki K, Doukas C, Kanakakis J, Anastasiou E, Mantzou E, Alevizaki M: Severity of cardiovascular disease in girls: relation with exposure to endogenous estrogen. Maturitas 2006, 55:517. 10. Carr MC: The emergence in the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003, 88:2404411. 11. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26 year adhere to up of participants in the Framingham Heart Study. Circulation 1983, 67:96877. 12. Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer G, Hudson S, Luger A, Lemmens-Gruber R: Sex-specific variations in metabolic control, cardiovascular danger, and interventions in sufferers with form two diabetes mellitus.Tandospirone 5-HT Receptor Gend Med 2010, 7:57183.Rinucumab Inhibitor 13. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, Stamler R, Smith D, Collette P, Stamler J: Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart illness mortality in guys and women. Am J Epidemiol 1986, 123:50416. 14. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, three:46324. 15. Asztalos BF, Schaefer EJ: HDL in atherosclerosis: actor or bystender Atherosclerosis 2003, four(Suppl 1):219. 16. Hayden MR, Tyagi SC: Isolated low high density lipoprotein-cholesterol (HDL-C): implications of international threat reduction.PMID:22943596 Case report and systematic scientific critique. Cardiovasc Diabetol 2005, 4(1):1. 17. Taskinen MR: Diabetic dyslipidemia: from simple research to clinical practice. Diabetologia 2003, 46:73349. 18. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ: Distribution of ApoA-I-containing HDL subpopulations in sufferers with coronary heart illness. Arterioscler Thromb Vasc Biol 2000, 20:2670676. 19. Pirillo A, Norata GD, Catapano AL: High-density lipoprotein subfractions what the clinicians should know. Cardiology 2013, 124:11625. 20. Mackness MI, Durrington PN, Mackness B: The function of paraoxonase 1 activity in cardiovascular disease: possible for therapeutic intervention. Am J Cardiovasc Drugs 2004, four:21117. 21. Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001, 15:2073084. 22. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D: Inflammation, adiponectin, obesity and cardiovascular danger. Curr Med Chem 2010, 17:4511520.23. Huang SS, Huang PH, Chen YH, Chiang KH, Chen JW, Lin SJ: Association of adiponectin with future cardiovascular events in patients following acute myocardial infarction. J Atheroscl.